Starpharma Holdings (ASX:SPL) Net Margin %: 12.62% (As of Dec. 2025)


ASX:SPL Starpharma Holdings Ltd ASX:SPL
52 GF Score
Price A$0.70
GF Value A$0.43
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Net Margin %?

Starpharma Holdings ASX:SPL +0.72% 52 Net Margin % is 12.62% as of Dec. 2025. GuruFocus rates ASX:SPL with a GF Score™ of 52/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Starpharma Holdings ranks better than 61.63% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Starpharma Holdings's Net Income for the six months ended in Dec. 2025 was A$1.37 Mil. Starpharma Holdings's Revenue for the six months ended in Dec. 2025 was A$10.83 Mil. Therefore, Starpharma Holdings's net margin for the quarter that ended in Dec. 2025 was 12.62%.

The historical rank and industry rank for Starpharma Holdings's Net Margin % or its related term are showing as below:

ASX:SPL' s Net Margin % Range Over the Past 10 Years
Min: -1097.44   Med: -307.42   Max: 274.06
Current: -23.32

ASX:SPL's Net Margin % is ranked better than
61.63% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs ASX:SPL: -23.32

Starpharma Holdings  (ASX:SPL) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Starpharma Holdings Net Margin % Related Terms

Starpharma Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Net Margin % Chart

Starpharma Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,097.44 -345.02 -532.09 -98.50 -203.38

Starpharma Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.37 -653.02 -285.59 -152.05 12.62

ASX:SPL vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Starpharma Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Starpharma Holdings Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's Net Margin % falls into.


ASX:SPL
52GF Score
Starpharma Holdings Ltd ASX:SPL
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Starpharma Holdings's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-9.99/4.912
=-203.38 %

Starpharma Holdings's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=1.367/10.832
=12.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 12.62% mean?
Starpharma Holdings (ASX:SPL) has a Net Margin % of 12.62% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Starpharma Holdings and its competitors. According to the industry distribution chart, Starpharma Holdings ranks #363 out of 946 companies in the Biotechnology industry, placing it in the top 38.4%.
Is Starpharma Holdings' Net Margin % too high?
Starpharma Holdings' current Net Margin % is 12.62%. Based on the distribution chart, Starpharma Holdings ranks #363 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Starpharma Holdings has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #363 out of 946 companies for Net Margin %. This puts Starpharma Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current Net Margin % is 12.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current Net Margin % is 12.62%. Starpharma Holdings' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Net Margin % is 12.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Net Margin %: 12.62%
  • GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
52GF Score

Get the complete analysis for ASX:SPL

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.70
Price
A$0.43
GF Value